ArticleEuropean journal of nuclear medicine and molecular imaging2014
Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy.
Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Pooled it
- Advanced Heart Block and Asystole After Regadenoson Infusion: When Cautionary Tales Become Reality.Cureus · 2023Article
- Asystole following Regadenoson administration: Review of literature, risk factors and management.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Review
- Gender-related differences in side-effects and hemodynamic response to regadenoson in patients undergoing SPECT myocardial perfusion imaging.European journal of nuclear medicine and molecular imaging · 2019Article
- Adverse effects associated with regadenoson myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Regadenoson-induced complete heart block and asystole: A real possibility nuclear laboratories should be aware of.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- Regadenoson in Myocardial Perfusion Study - First Institutional Experiences in Bosnia and Herzegovina.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2016Article
- EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision.European journal of nuclear medicine and molecular imaging · 2015Article
- Asystole following regadenoson infusion in stable outpatients.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2014Article
- Serious complications associated with regadenoson administration for myocardial perfusion imaging: a commentary.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2014Article
- Regadenoson-induced bradycardia and hypotension: possible mechanism and antidote.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2014Article
- Regadenoson for myocardial perfusion imaging: Is it safe?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRegadenoson was approved for clinical use in Europe in 2011. Since then, it has become the default form of stress at our institution. We have assessed the side-effect profile and tolerability of regadenoson in patients undergoing clinically indicated myocardial perfusion scintigraphy between July 2011 and July 2012.
methodsClinical, stress and imaging data were recorded prospectively. Symptoms during stress were recorded and defined as mild, moderate or severe. An adverse event was defined as any symptom that persisted for more than 30 min or that required investigation or treatment.
resultsOf 1,764 consecutive patients, 1,581 (90%) received regadenoson combined with submaximal exercise unless contraindicated. Symptoms were common (63%) but transient and well-tolerated. The severity of symptoms was recorded in most patients as mild (84%). Dyspnoea (36%) and chest discomfort (12%) were the commonest side effects. Adverse events were reported in eight patients (0.5%), thought to be vasovagal in seven of these. All patients recovered fully without sequelae. There were no deaths, myocardial infarction or hospital admissions. Regadenoson stress was performed in 206 patients (12%) with asthma or chronic obstructive pulmonary disease (COPD) without bronchospasm or any other major side effect.
conclusionWe studied the symptom profile of regadenoson in the largest European cohort to date. Regadenoson combined with submaximal exercise was well tolerated, notably also in patients with asthma or COPD. The majority of regadenoson-related adverse events were vasovagal episodes without sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.